WINNIPEG, MANITOBA--(Marketwire - Feb. 4, 2013) - Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce that it will receive the Life Science Company of the Year Award from the Life Science Association of Manitoba at an awards ceremony on February 13, 2013. The award is presented annually to a private sector company based in Manitoba that has made a positive impact on the life sciences sector in the past year and is active in paving the road toward future wealth and job creation in the province. Past Life Science Company of the Year Award winners include IMRIS, Biovail and Cangene.
The Life Science Association of Manitoba (LSAM) presents its annual Life Science Awards as a way to recognize the leaders and innovators of the life science community. With its selection as Life Science Company of the Year, Miraculins has been recognized for distinguishing itself from its peers with strong overall company performance, demonstrating leadership and showing significant achievement.
"We are pleased to acknowledge Miraculins as the Life Science Company of the Year for 2012," said Tracey Maconachie, President of LSAM. "The life science industry in Manitoba, which now accounts for 7% of the province's GDP, is loaded with exceptional companies, with Miraculins serving as a prime example of the type of burgeoning life science success stories that Manitoba is offering the world."
"We are honoured to have been recognized by LSAM for our accomplishments to date, and for our potential as we move forward," said Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. "We are proud to share news of this award with our shareholders, investors and customers, without whom we would not have been able to reach this point in our corporate development. Furthermore, we are pleased to be acknowledged amongst the many deserving life science companies in Manitoba, and are proud to be a part of this important sector, with a very supportive industry association and a provincial government with a true appreciation for innovation."
August 10, 2012 07:00 ET
Miraculins to Receive $130,000 Grant for PreVu® from the Province of Manitoba
WINNIPEG, MANITOBA--(Marketwire - Aug. 10, 2012) - Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce that it will receive $130,000 in grant funding from the Manitoba Commercialization Support for Business (CSB) Program to support commercialization of its PreVu® Non-Invasive Skin Cholesterol Test.
The Province of Manitoba's CSB Program assists Manitoba entrepreneurs and businesses seeking to develop and commercialize innovative products and processes, and expand into new markets. The Program provides financial assistance to cost share eligible arms-length third party expenses on a 50/50 basis. All assistance will be tied to mutually agreed upon milestones and financial assistance may be required to be paid back in full in the event that the company is sold, or relocates its Manitoba operations outside of the province during the life of the project.
"We are pleased to receive this support from the Province of Manitoba for our PreVu® technology," stated Christopher Moreau, President and CEO of Miraculins Inc. "The Province of Manitoba is active in cultivating a climate of innovation, and supporting businesses throughout the product development lifecycle. Miraculins is proud to be acknowledged, through this grant, for our potential and our role in the local life sciences community."